{"entity":{"id":"nct07105852","kind":"trial","name":"Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma","aka":[],"tldr":"A phase 2 trial of sacituzumab tirumotecan and pucotenlimab in gallbladder cancer and other biliary tract cancers, run by Sir Run Run Shaw Hospital, now recruiting.","summary":"Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma is a phase 2 interventional study registered as NCT07105852 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 59 participants, started 2025-07-03 and due to reach its primary completion in 2027-07-01. Interventions recorded: Sacituzumab tirumotecan (iv)+Putolizumab injection (iv). Conditions listed: Cholangiocarcinoma. Gallbladder cancer is named in the registry entry: \"* 1\\. Age \\>= 18 years old; 2. Histologically confirmed unresectable or metastatic cholangiocarcinoma (including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07105852","url":"https://clinicaltrials.gov/study/NCT07105852"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["sacituzumab-tirumotecan","pucotenlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07105852","phase":"2","setting":"Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma","sponsor":"Sir Run Run Shaw Hospital","enrolled":59,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07105852/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}